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Background: The estimated ratio of hereditary breast/ovarian cancer (HBOC) based on family history is 1.5% in
Latvia. This is significantly lower than the European average of 5–10%. Molecular markers like mutations and SNPs
can help distinguish HBOC patients in the sporadic breast and ovarian cancer group.
Methods: 50 patients diagnosed with HBOC in the Latvian Cancer Registry from January 2005 to December 2008
were screened for BRCA1 founder mutation-negatives and subjected to targeted resequencing of BRCA1 and BRCA2
genes. The newly found mutations were screened for in the breast and ovarian cancer group of 1075 patients by
Real Time-PCR/HRM analysis and RFLP.
Results: Four BRCA2 mutations including three novel BRCA2 frameshift mutations and one previously known BRCA2
frameshift mutation and one BRCA1 splicing mutation were identified. Two of the BRCA2 mutations were found in a
group of consecutive breast cancer patients with a frequency of 0.51% and 0.38%.
Conclusions: Molecular screening of sequential cancer patients is an important tool to identify HBOC families.
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Breast and ovarian cancers are the most common and
increasing cancers among women worldwide. From the
breast/ovarian cancer cases in Europe 5–10% are diag-
nosed as hereditary [1] which frequently have early onset
[2]. The most common approach to diagnosing heredi-
tary cancer is to investigate family history. However, her-
editary breast/ovarian cancer (HBOC) is often difficult
to identify by family history due to the small size of fam-
ilies and uncertain family history records [3]. The inci-
dence of hereditary cancer (diagnosed according to the
National Comprehensive cancer network (NCCN) guide-
lines) is 1.5% of all the breast cancers in Latvia [3]. This
is significantly lower than the European average. In other
words, many HBOC patients may be unnoticed among
the cancer patients considered sporadic, missing an op-
portunity to be clinically consulted for risk control.* Correspondence: edvins.miklasevics@rsu.lv
Institute of Oncology, Riga Stradins University, Dzirciema street 16, LV1007,
Riga, Latvia
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reproduction in any medium, provided the orMolecular screening of all cancer patients in order to re-
veal pathogenic high-penetrance mutations is an obvious
alternative. Mutations in the BRCA1 and BRCA2 genes
are known as the main risk factors of HBOC and are
found in about 80% of patients [4,5]. In Latvia, two
founder mutations, c.4035delA and c.5266dupC, of the
BRCA1 gene dominate [6,7], but no prevalent BRCA2
mutation has been reported as yet. Molecular screening
of consecutive breast and ovarian cancer patients re-
vealed that 3.77% of breast cancer and 9.9% of ovarian
cancer patients had been harboring one of the BRCA1
founder mutations [2]. Identification of new frequent
mutations in either of these genes would promote the
identification of more HBOC patients without substan-
tial cost increases.
This study provides the results of our attempt to iden-
tify new BRCA1/2 mutations in HBOC patients and esti-
mate their usefulness for molecular screening to spot
hidden hereditary breast/ovarian cancer patients without
a significant family history.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Polymorphisms found in the BRCA1 and BRCA2









BRCA1 c.2311T>C L771L rs16940 No 3
c.3113A>G E1038G rs16941 No 2
c.4308T>C S1436S rs1060915 No 4
c.4675+
1G>A
INV15+1 rs80358044 Yes 1
c.4837A>G S1613G rs1799966 No 1
BRCA2 c.-41A>G 5'UTL - Unkown 1
c.-26G>A 5'UTL rs1799943 No 20
c.658delGT V220 (223stop) rs80359604 Yes 1
c.1114A>C N372H rs144848 No 1
c.3396A>G K1132K rs1801406 No 10
c.3807T>C V1269V rs543304 No 2
c.4258G>T D1420Y rs28897727 No 2




c.5744C>T T1915M rs4987117 minor 2




1 As clinically significant were considered nonsense, frameshift and splice site
mutations, as well as missense ones which are considered as such in Breast
Cancer Information Core database [16].
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Study population
50 unrelated patients who had been diagnosed with
HBOC from January 2005 to December 2008, according
to the NCCN guidelines.
Blood samples for the study material had been col-
lected from consecutive 1075 breast or ovarian cancer
patients at Pauls Stradins Clinical University Hospital
from January 2005 to December 2008. These patients
had been screened for BRCA1 founder mutations
c.181T>G (BIC: 300T>G), c.4035delA (BIC: 4154delA)
and c.5266dupC (BIC: 5382insC) and found negative
earlier [2]. All patients have been informed of the ana-
lyses, and they have given written consent to have their
blood samples used for DNA analyses. Permission for
the research project has been given by the Ethical Com-
mittee of Riga Stradins University.
Families which had at least three breast, ovarian or
breast and ovarian cancer patients and one of those pa-
tients was the first degree relative to other two or the
second degree relative through male were classified as
HBC, HOC or HBOC families, respectively.
BRCA1 and BRCA2 analysis
Genomic DNA was isolated from peripheral blood cells
using the FlexiGene DNA Kit (Qiagen, Germany).
Screening of the three most common BRCA1 mutations
in Latvia, c.181T>G (BIC: 300T>G), c.4035delA (BIC:
4154delA) and c.5266dupC (BIC: 5382insC), was
performed by multiplex PCR. The samples without
BRCA1 founder mutations were subjected to direct se-
quencing of the coding regions of BRCA1 and BRCA2
genes and analyzed by ABI PRISM 3130 (Applied
Biosystems, USA).
Screening of the BRCA2 c.658delGT mutation was
performed by Real Time PCR/High Resolution Melting
(HRM) run on Rotor-Gene 6000 amplification (Qiagen,
Germany). BRCA2 c.5244delC and c.7316delG muta-
tions were screened by restriction fragment length poly-
morphism (RFLP) analysis. The PCR products were
digested with AluI and BccI restriction enzymes (NEB,
England), respectively. All the mutations detected in
HRM and RFLP were confirmed by sequencing. All the
primers were as described before [8].
Results
50 unrelated families who corresponded to the NCCN
guidelines for HBOC (23 families), HBC (25) and HOC
(2) were identified in Latvia from 2005 to 2008. The ethnic
composition of the group matched the ethnic structure of
the country: 27 Latvian (54% of the HBOC families and
59% of the residents in Latvia), 16 Russian (32% and 28%),
3 Polish (6% and 2.3%), 2 Belarusian (4% and 3.6%)
and 2 Ukrainian (4% and 2.5%) families. Screening forthree BRCA1 mutations (c.181T>G, c.4035delA and
c.5266dupC) revealed that 15 families were (10 HBOC,
3 HBC and 2 HOC) harboring either mutation
c.4035delA (8 families) or c.5266dupC (7 families). The
distribution of the BRCA1 mutations by ethnicity was
as follows: 8 Latvian (29.6% of hereditary cancer fam-
ilies from the same ethnic group), 1 (6%) Russian, 3
(100%) Polish, 2 (100%) Ukrainian and 1 (50%) Bela-
rusian. From the remaining 35 patients, 30 agreed to
targeted resequencing of the BRCA1/2 genes.
Four clinically significant mutation and thirteen poly-
morphisms [9-15] in the BRCA1 and BRCA2 genes were
identified by targeted resequencing (Table 1).
777 consecutive breast cancer and 298 consecutive
ovarian cancer patients were screened for the presence
of any of the three BRCA2 mutations found in heredi-
tary cancer families. To detect the c.658delGT variant,
Real Time PCR/HRM of exon 8 was performed. Two
different melting patterns compared to the wild-type
were found in 7 cases. The PCR fragments with different
melting curves were sequenced and harbored either the
c.658delGT or c.646delG mutation (Table 2). None of
these mutations were found among the 298 ovarian can-
cer patients. No other carriers of mutations c.5244delC
and c.7316delG were identified (Table 2).
Table 2 Mutations found in the BRCA2 gene in








c.646delG A216 (229stop) 3 BC/39,44,58
c.658delGT V220 (223stop) 4 BC/43,51,55,73
c.5244delC S1748 (1748stop) 0
c.7316delG G2439 (2468stop) 0
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cancer group were identified as carriers of the c.658delGT
mutation. In three non-HBOC patients the c.646delG mu-
tation was found. Figure 1 shows family pedigrees of pa-
tients. Size of family for all patients is relatively small and
some patients don’t have previously known cancer cases
in family. None of pedigrees of patients from consecutive
patients group corresponded to criteria of HBOC.Figure 1 Family pedigrees of the patients with an identified BRCA2 c.
patient from HBOC group, A – H – patients from consecutive patients grou
cancer localization are marked in gray (Pro, prostate; Ut, uterus; Bl, bladder;
mutations were found by molecular screening are indicated by arrows andDiscussion and conclusions
In a previous study, we had screened for BRCA1 founder
mutations c.4034delA and c.5266dupC in consecutive
breast/ovarian cancer patients, and it showed that 57.5%
of mutation carriers did not correspond to the clinical
criteria of HBC or HBOC [2]. This indicates that a sig-
nificant number of patients carrying BRCA1 or BRCA2
mutation are still missing an opportunity of proper
counseling or surveillance of other family members. The
main reason for an insufficient detection of HBOC pa-
tients based on family histories is due to the small family
size resulting into a small number of relatives. In fam-
ilies with a larger number of relatives it is easier to diag-
nose hereditary cancer. The significant difference in the
size of the families who were diagnosed with hereditary
cancer syndromes, according to defined criteria, and in
the families with non-diagnostic findings has been de-
scribed previously in the population screening of the658delGT (A-E) and c.646delG (F-H) mutation. A family pedigree of
p. Breast cancer patients are marked in black. Patients with other
HN, head and neck; St, stomach). The patients in whom BRCA2
information about mutation added to proband.
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relatives within the families with hereditary cancer syn-
dromes, according to criteria, was 13.6, whereas it was
9.5 for the families not diagnosed with hereditary cancer
syndrome but whose members were carriers of the
BRCA1 founder mutation. In the case of hereditary
breast cancer, clinical findings based on family history
do not overlap with the results of molecular screening,
and molecular screening reveals more mutation carriers
than clinical criteria.
Our findings show that in total seven patients not di-
agnosed with HBOC based on family history were har-
boring deleterious mutation in BRCA2. One of the
mutations which was found in the non-HBOC group of
this study, c.658delGT, is listed in the BIC database
(886delGT) [16]. This mutation has also been reported
as a genetic risk factor of brain tumor development in
the Fanconi anaemia group D1 [13,17]. The frequency of
the mutation c.658delGT in BRCA2 is 0.9% in Polish
ovarian-stomach and ovarian cancer families [18], 1.9%
in Portuguese breast cancer families [19] and 0.09% in
American breast cancer patients [20]. The frequency of
the c.658delGT mutation in BRCA2 in this study was 2%
in the HBOC patient group and 0.51% in the consecutive
breast cancer patient group. This is the most common
BRCA2 mutation in Latvia. To our best knowledge, the
BRCA2 c.646delG mutation has not been reported as
yet.
Despite finding 10 BRCA2 mutation carriers in the
breast cancer patients, we did not find any BRCA2 mu-
tation carriers in the ovarian cancer patients. Due to the
small number of ovarian cancer patients in the HBOC
patient group, we might have missed the BRCA2 muta-
tions which tend to affect the risk of ovarian cancer.
Inspecting the pedigree charts of BRCA2 mutation car-
riers for ovarian cancer families, just one ovarian cancer
family member in a BRCA2 c.7316delG carrier family
was found. However, the relation between ovarian cancer
and the BRCA2 mutation is uncertain because we did
not analyze the mutation status of other family members
except the proband.
In this study, we found BRCA2 mutations with prob-
able founder effect in patients without a significant fam-
ily history using molecular screening. It can be useful to
screen all consecutive breast cancer patients for the spe-
cific BRCA1 and BRCA2 mutations with founder effect.
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